St. Louis Clinical Trials
St. Louis, MO
Daniel Gruener, MD, Vice President of Medical and Scientific Affairs, is board certified by the American Academy of Psychiatry and Neurology and by the American Academy of Pain Management. He has over 20 years of experience and has conducted more than 250 clinical trials in pain, addiction, psychiatry and neurology disorders. Dr. Gruener has been a thought leader in pain for more than 20 years, and has served as a board member of the American Pain Society. Additionally, he has written several books, and most significantly, he co-authored a textbook on pain and is the senior editor for Pain Control in the Primary Care Setting, published by the APS, which was the standard of care for several years.
Rick Mofsen, DO, Chief Medical Officer for Evolution Research Group, founded St. Louis Clinical Trials in 1998. He is board certified by the American Osteopathic Board of Neurology and Psychiatry as well as by the American Academy of Pain Management. Dr. Mofsen has been an investigator on over 250 CNS and pain trials. 1993, Dr. Mofsen founded Long-Term Psychiatric Management, and currently serves as an advisor to this group. Long-Term Psychiatric Management provides psychiatric consultation and management to more than 100 long-term care and residential facilities in the St. Louis area, and is a primary recruitment source for St. Louis Clinical Trials research programs.
St. Louis Clinical Trials
St. Louis Clinical Trials is a proven and trusted resource for the conduct of complex Phase Ib/IIa studies in Schizophrenia, Major Depressive Disorder, Bipolar Mania, Alzheimer’s disease, Addiction and Pain Management. The research staff is proficient in all standard rating scales and is highly experienced in the conduct of specialized and complex study designs, which include cardiac monitoring (TQT/ QTc), polysomnography (PSG), intensive pharmacokinetic sampling and qEEG. The site’s recruitment team has developed a solid infrastructure for identifying quality research subjects throughout the greater St. Louis region, resulting in meeting and exceeding enrollment targets on the vast majority of its trials.
A private, inpatient and outpatient research facility, St. Louis Clinical Trials is focused on Phase I-III clinical trials in a variety of therapeutic indications. The purpose-built, 55-bed facility is fully equipped, secure, locked and supported by highly experienced M.D.s, D.O.s, Nurse Practitioners, Paramedics, Patient Care Technicians, C.R.C.s, Pharmacists (Pharm.D.), Laboratory Technicians and Regulatory Specialists. The research staff is proficient in all standard rating scales and is highly experienced in the conduct of specialized and complex study designs. These include cardiac monitoring (TQT/QTc), polysomnography (PSG), intensive pharmacokinetic sampling and qEEG.
The facility maintains a compounding pharmacy with an enclosed HEPA filter hood; a double-locked, limited access drug storage room with a 24-hour monitoring system; an IATA and CLIA certified processing laboratory; and -20 degree and -70 degree sample storage. ECGs are performed at the clinic, and radiology facilities (X-ray, PET, CT, MRI, fMRI) are located nearby. In addition, St. Louis Clinical Trials has formed a relationship with The Center for Clinical Imaging Research (CCIR) at Washington University where highly specialized imaging studies such as fMRI and PET are now performed. This Medical Services Agreement gives St. Louis Clinical Trials access to a variety of services available only at a select few locations worldwide. The research clinic has dedicated monitor rooms with high-speed internet for remote data entry access, on-site long-term storage, a conference room, lobby waiting area and free parking. There is also an indoor smoking room as well as a dedicated, controlled and secure outdoor smoking space.
Senior Director, Clinical Operations and Site Development
- Alzheimer’s Disease
- Bipolar Disorder
- Essential Tremor
- Movement Disorders
- Opioid Use Disorder
- Pain (Acute & Chronic)
- Sleep Disorders
- Smoking Cessation
Institutional Review Board